Alzheimer’s Drugs and Medicare: A Case For Pre-Approval Discussions
Medicare's Part D plan bidding schedule and uncertainty over the Alzheimer’s drug pipeline is putting plan sponsors in a difficult situation as they contemplate their 2018 bids.
You may also be interested in...
The promise of outcomes-based contracts for biopharmaceuticals has yet to be realized in the US. Although precise numbers are hard to come by, payers and manufacturers agree the field is still nascent. However, they don’t seem to be giving up on the idea.
Manufacturers should be allowed to talk to payer representatives involved in financial forecasting about a new drug well before FDA approval, group led by Academy of Managed Care Pharmacy says.
PhRMA Senior Counsel Jeffrey Francer offers three-step reform approach to loosening FDA’s restrictions, beginning with the 'low-hanging fruit' of talking with payers.